Actiphage is unique as it is able to detect and identify live mycobacteria at a very early stage of infection,...
Faster testing time
Actiphage only requires one visit to collect blood samples and analysis takes 6-8 hours to produce a result.
No ‘cool off’ period
There is no time limit between tests, enabling a continuous programme of testing to be carried out where infection has been detected or is suspected.
Highly sensitive
The test only works on viable mycobacteria. Actiphage is more sensitive than any other test currently available, able to detect fewer than 10 live mycobacteria in a 2ml blood sample.
Highly specific
The technology has in-built high-level specificity controls and is able to identify any species of mycobacteria that is susceptible to the bacteriophage, including MAP (Johne’s disease) and M.bovis (bovine TB).
High accuracy
Actiphage can reproducibly distinguish between live and dead mycobacteria, meaning that a positive result will only be delivered if there are live mycobacteria in the sample.
As a tool for differentiating vaccinated from infected hosts
Uniquely, Actiphage directly detects live mycobacteria so will always produce a negative result when used on vaccinated subjects even if they might have a positive skin test result. This opens up the possibility of, for example, the roll-out of vaccination programmes.
Actiphage has potential as a non-invasive screening tool for high-risk populations. It is able to detect mycobacteria in the blood, evidence of disease progression.
This is a vital first step towards eradication of devastating mycobacterial disease.
Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom
More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB
Read MoreDelighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies
Read MoreTesting 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease
Read More